Table IV.
Summary of studies that assessed glypican-3 inhibitors in the treatment of HCC.
| Model | Summary | Cell type | (Refs.) |
|---|---|---|---|
| Human | Human monoclonal antibody targeting glypican-3 prevents the migration and motility of HCC | Hep3B and HepG2 | (83) |
| Glypican-3-targeted chimeric antigen receptor T cell provides a promising therapeutic target for glypican-3-positive HCC | HepG2, Hep3B, PLC/PRF/5 and SK-Hep-1 | (84) | |
| Silencing the glypican-3 gene protects against HCC | HepG2 | (85–87) | |
| Interfering glypican-3 gene transcription blocks HCC cell apoptosis and prevents metastasis via the Wnt/β-catenin signaling pathways | MHCC-97H and Huh7 | (88) | |
| hGC33 protects patients with HCC | Liver cells | (89–91) | |
| By targeting glypican-3, microRNA-219-5p exerts antitumor effects in HCC | Liver cells | (92) | |
| Rat | Anti-glypican-3 antibody protects against HCC | RH7777 | (93) |
| Anti-glypican-3 antibody exerts antitumor and hepatoprotective effects against HCC | Liver cells | (34) | |
| Mice | Targeted photoimmunotherapy for glypican-3 combined with nanoparticle albumin-bound paclitaxel is a promising method for treating HCC | Liver cells | (94) |
| Glypican-3 cDNA vaccine by using a recombinant plasmid encoding murine glypican-3 cDNA for treatment of HCC produces specific and effective antitumor immunity against HCC | Liver cells | (95) |
HCC, hepatocellular carcinoma.